共 50 条
- [31] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases[J]. British Journal of Cancer, 2017, 116 : 1558 - 1563Sagun ParakhJohn J ParkShehara MendisRajat RaiWen XuSerigne LoMartin DrummondCatherine RoweAnnie WongGrant McArthurAndrew HaydonMiles C AndrewsJonathan CebonAlex GuminskiRichard F KeffordGeorgina V LongAlexander M MenziesOliver KleinMatteo S Carlino
- [32] Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy[J]. FRONTIERS IN ONCOLOGY, 2019, 9Fareed, Muhammad MohsinPike, Luke R. G.Bang, AndrewMai Anh HuynhTaylor, AllisonSpektor, AlexanderAwad, Mark M.Ott, Patrick A.Krishnan, MonicaBalboni, Tracy A.Schoenfeld, Jonathan D.
- [33] Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated with Anti-PD-1 Therapy[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E217 - E217Fareed, M. M.Pike, L. R. G.Bang, A.Taylor, A.Spektor, A.Awad, M. M.Ott, P.Krishnan, M. S.Balboni, T. A.Schoenfeld, J. D.
- [34] Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1[J]. CLINICAL CANCER RESEARCH, 2023, 29 (05) : 858 - 865Robert, CarolineLebbe, CelesteLesimple, ThierryLundstrom, EijaNicolas, ValerieGavillet, BrunoCrompton, PhilippaBaroudjian, BarouyrRoutier, EmilieLejeune, Ferdy J.
- [35] FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma[J]. ANNALS OF ONCOLOGY, 2022, 33 (01) : 99 - 106Dimitriou, F.Lo, S. N.Tan, A. C.Emmett, L.Kapoor, R.Carlino, M. S.Long, G., VMenzies, A. M.
- [36] Clinical Factors Associated with Progression in Previously Treated Patients with Metastatic NSCLC on ANTI-PD-1 Therapy[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1142 - S1142Randall, M.Kollipara, R.Basu, S.Borgia, J.Batus, M.Bonomi, P.Tarhoni, I.Fughhi, I.Fidler, M.
- [37] Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (05)Wagner, Nikolaus B.Lenders, Max M.Kuehl, KathrinReinhardt, LydiaAndre, FionaDudda, MilenaRing, NatalieEbel, ChiaraStaeger, RamonZellweger, CarolineLang, RolandPaar, MichaelGussek, PhilippRichtig, GeorgStuermer, Suzan H.Kimeswenger, SusanneOellinger, AngelaForschner, AndreaLeiter, UlrikeWeide, BenjaminGassenmaier, MaximilianSchraag, AmadeusKlumpp, BernhardHoetzenecker, WolframBerking, CarolaRichtig, ErikaZiemer, MirjanaMangana, JohannaTerheyden, PatrickLoquai, CarmenNguyen, Van AnhGebhardt, ChristofferMeier, FriedegundDiem, StefanCozzio, AntonioFlatz, LukasRoecken, MartinGarbe, ClausEigentler, Thomas K.
- [38] Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E635 - E635Liniker, E.Kong, B.Menzies, A. M.Cooper, A. J.Kefford, R. F.Fogarty, G. B.Guminski, A.Carlino, M. S.Wang, T. W.Long, G. V.Hong, A.
- [39] Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure[J]. MELANOMA RESEARCH, 2021, 31 (05) : 464 - 471Klee, GinaKurzhals, JonasHagelstein, VictoriaZillikens, DetlefRecke, AndreasLangan, Ewan A.Terheyden, Patrick
- [40] Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome[J]. CANCER RESEARCH, 2017, 77Gopalakrishnan, VancheswaranSpencer, ChristineReuben, AlexandrePrieto, PeterVicente, DiegoKarpinets, Tatiana V.Hudgens, Courtney W.Hutchinson, Diane S.Tetzlaff, MichaelLazar, AlexanderDavies, Michael A.Gershenwald, Jeffrey E.Jenq, RobertHwu, PatrickSharma, PadmaneeAllison, JamesFutreal, AndrewAjami, NadimPetrosino, JosephDaniel-MacDougall, CarrieWargo, Jennifer A.